Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánchez Torres
{"title":"PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study.","authors":"Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánchez Torres","doi":"10.2217/lmt-2021-0008","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain.</p><p><strong>Methods: </strong>Multicenter, retrospective study.</p><p><strong>Results: </strong>Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1.</p><p><strong>Conclusion: </strong>PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 4","pages":"LMT53"},"PeriodicalIF":0.7000,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/81/lmt-10-53.PMC8656292.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2021-0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 1
Abstract
Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain.
Methods: Multicenter, retrospective study.
Results: Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1.
Conclusion: PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
